Topics

PubMed Journals Articles About "Effects Of Gallopamil In Severe Asthma" RSS

05:30 EST 18th February 2020 | BioPortfolio

Effects Of Gallopamil In Severe Asthma PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Effects Of Gallopamil In Severe Asthma articles that have been published worldwide.

More Information about "Effects Of Gallopamil In Severe Asthma" on BioPortfolio

We have published hundreds of Effects Of Gallopamil In Severe Asthma news stories on BioPortfolio along with dozens of Effects Of Gallopamil In Severe Asthma Clinical Trials and PubMed Articles about Effects Of Gallopamil In Severe Asthma for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Effects Of Gallopamil In Severe Asthma Companies in our database. You can also find out about relevant Effects Of Gallopamil In Severe Asthma Drugs and Medications on this site too.

Showing "Effects Gallopamil Severe Asthma" PubMed Articles 1–25 of 29,000+

Severe asthma: what is new in the new millennium.

Severe asthma remains a debilitating disease and a challenge for the clinicians. Novel therapies have been introduced and have greatly improved asthma control and more are under development or in clinical studies. These include anti-IL5/IL5R, anti-IL4/IL4R, anti IL13, anti- thymic stromal lymphopoietin (TSLP) and more, and severe asthma is currently managed in personalized medicine approach. However, there is still an unmet need to discover new, clinically available biomarkers and targeted therapies for a l...


Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR).

To date, clinical characteristics of the international severe asthma population are unknown. Inter-country comparisons are hindered by variable data collection within regional/national severe asthma registries. Our aim was to describe demographic and clinical characteristics of patients managed in severe asthma services in the USA, Europe, and Asia/Pacific region.

The Prevalence, Characteristics, and Patient Burden of Severe Asthma Determined by Using a Japan Health Care Claims Database.

Recently, several new biological drugs targeting severe asthma are on the market, and various studies on severe asthma have been reported worldwide. However, in Japan, the data are still limited regarding epidemiology and burden of disease on severe asthma. This study determined the prevalence, characteristics, and burden of disease of patients with severe asthma.


Severe asthma during childhood and adolescence: A longitudinal study.

Morbidity and mortality associated with childhood asthma are driven disproportionately by children with severe asthma. However, it is not known from longitudinal studies whether children outgrow severe asthma.

Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma.

: Thymic stromal lymphopoietin (TSLP) is overexpressed in the airways of severe asthmatics and is an upstream cytokine that orchestrates inflammatory responses in asthma. TSLP exerts its effects by binding to a high affinity heteromeric receptor complex composed of TSLPR and IL-7Rα. An association of polymorphisms in TSLP with airway hyperresponsiveness, IgE, eosinophilia and asthma has been documented. TSLP has been implicated in asthma pathophysiology. Tezepelumab is a first-in-class human monoclonal ant...

Hot Topic: Precision Medicine for Asthma-Has the Time Come?

Asthma is a common inflammatory airway disease, which affects more than 300 million people worldwide. Although conventional drugs are effective for most of the patients with mild-to-moderate asthma, they are less effective for patients with difficult-to-treat or severe asthma. Identification of asthma endotypes and biomarkers will lead to more precise approaches to treat asthma.

Precision medicine in severe pediatric asthma: opportunities and challenges.

Severe pediatric asthma exerts a substantial burden on patients, their families and society. This review provides an update on the latest insights and needs regarding the implementation of precision medicine in severe pediatric asthma.

It's Time to Start Phenotyping Our Patients with Asthma.

Advances in the management of pediatric asthma, including biologics, offer practitioners the ability to tailor therapies to individual patients. However, asthma treatment guidelines have not kept up with current studies. This review explores the current literature incorporating the use of phenotyping in pediatric patients with asthma to provide precision therapy. Biomarkers can be used to more accurately predict the development of asthma, identify features that may be associated with difficult-to-control or...

The Current State of Biologic Therapies for Treatment of Refractory Asthma.

Asthma is a heterogeneous disease, with the immune processes behind the chronic inflammation underlying this disorder differing between the various identified asthma endotypes. In addition to heterogeneity in underlying disease pathophysiology, asthmatics fall across a broad spectrum of disease severity and can vary greatly in their response to convention asthma therapies. A small percentage of patients with severe persistent asthma will remain uncontrolled despite treatment with high-dose inhaled corticost...

Associated Factors for Asthma Severity in Korean Children: A Korean Childhood Asthma Study.

Childhood asthma has a considerable social impact and economic burden, especially in severe asthma. This study aimed to identify the proportion of childhood asthma severity and to evaluate associated factors for greater asthma severity.

Investigation of the relationship between IL-6 and type 2 biomarkers in severe asthma.

Combination of IL-6 (non-Type 2 asthma) and FeNO or blood eosinophil count (Type 2 asthma) identified asthma endotypes related to asthma severity, exacerbations, and responsiveness to corticosteroids and potential for response to anti-Type 2 and anti-IL-6 treatment.

Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma.

Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation, including immunoglobulin E (IgE)-mediated allergic inflammation in asthma. In the LIBERTY ASTHMA QUEST (NCT02414854) study, dupilumab reduced severe asthma exacerbations and improved forced expiratory volume in 1 second (FEV) in patients with uncontrolled, moderate-to-severe asthma with greater efficacy observed in patients with elevated type 2 inflammatory biomarkers (blood eosinophils a...

Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma.

Bronchial asthma is a chronic inflammatory disease characterized, in a percentage of patients, as an eosinophilic inflammation of the airways. Eosinophils are recognized as a proinflammatory granulocyte playing a major role in the T2-high phenotype, which includes severe eosinophilic asthma. Eosinophilic asthma represents the majority of the phenotypic variants clinically characterized by severity and frequent exacerbations. For patients with severe uncontrolled asthma, monoclonal antibodies are used as add...

Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.

Previous analyses examining the relationship between blood eosinophil count and mepolizumab treatment effects in severe eosinophilic asthma have used a range of doses and administration routes.

Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients.

In order to improve targeted therapeutic approaches for asthma patients, insights into the molecular mechanisms that differentially contribute to disease phenotypes, such as obese asthmatics or severe asthmatics, are required. Here we report immunological and microbiome alterations in obese asthmatics (n = 50, mean age = 45), non-obese asthmatics (n = 53, mean age = 40), obese non-asthmatics (n = 51, mean age = 44) and their healthy counterparts (n = 48, mean age = 39). Obesi...

Azithromycin as an add-on treatment for persistent uncontrolled asthma in adults: protocol of a systematic review and meta-analysis.

Clinical management of asthma remains a public challenge. Despite standard treatment with inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs), asthma remains uncontrolled in a substantial number of chronic asthma patients who risk reduced lung function and severe exacerbations. Azithromycin could have add-on effects for these patients. This study is proposed to systematically evaluate the efficacy of azithromycin as an add-on treatment for adults with persistent uncontrolled symptomatic asth...

What have recent advances in therapy taught us about severe asthma disease mechanisms?

: Severe asthma still represents a worldwide challenge. The need for further treatment options has stimulated basic and pharmacological research to focus on the immune and inflammatory background of asthma. The new biologic drugs express the considerable advances in the field and besides providing a revolutionary treatment option for severe asthma, contribute themselves to better understand the pathophysiologic mechanisms they address, paving the way to new potential targets. : A selective search on PubMed ...

Relationship between immune parameters during a severe exacerbation in allergic asthmatic children and asthma outcomes in the following year.

Despite improvement in asthma maintenance treatment, exacerbations remain important issues. They are markers of severe asthma but can also occur in mild asthma (1). Viruses, and mainly Rhinoviruses (RVs), are the main triggers, and they may interact with aeroallergen-specific immunoinflammatory pathways in atopic patients (2,3). Some studies have suggested that these episodes could be related to an alteration of innate immune defenses and particularly a defective production of type I and III interferons (IF...

Evaluating Direct Costs and Productivity Losses of Asthma Patients Receiving GINA 4/5 Therapy in the US.

Despite the low prevalence for all asthma patients, those with severe disease account for a disproportionately large economic burden.

Modern Innovative Solutions to Improve Outcomes in Severe Asthma: Protocol for a Mixed Methods Observational Comparison of Clinical Outcomes in MISSION Versus Current Care Delivery.

Asthma that is poorly controlled and undertreated can progress to more severe disease that is associated with high levels of unscheduled care that requires high-cost therapy, leading to a significant health economic burden. The identification and appropriate referral to a specialist asthma service is also often delayed by several months or years because of poor recognition and understanding of symptom severity. Current severe asthma services may take several months to provide a comprehensive multidisciplina...

Optimal Asthma Control: Time for a New Target.

The stepwise approach to pharmacological treatment in adult asthma mandates that asthma treatment is progressively stepped up to achieve symptom control and reduce the risk of exacerbations, and stepped down after a period of prolonged control. This review proposes that in adults without good asthma control, 'well-controlled' asthma can only be achieved in around 70% of patients across the strata of severity, and only if there is a progressive increase in ICS/LABA therapy to a maintenance ICS dose which cau...

The moderating role of allergy immunotherapy in asthma progression. Results of a population-based cohort study.

Allergic asthma causes substantial morbidity and constitutes a public health burden, which increases with asthma severity. There is evidence that allergy immunotherapy (AIT) prevents the progression from allergic rhinitis (AR) to asthma. However, evidence is missing on the potential of AIT to prevent progression from milder to more severe asthma.

Factors associated with effective inhaler technique among children with moderate to severe asthma.

Benralizumab Efficacy for Patients with Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma.

Choosing the right biologic for severe asthma: precision medicine through the lens of patient-centered decision making.


Quick Search